Research and Markets has announced the addition of the "Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016" report to their offering.

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016', provides in depth analysis on Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted pipeline therapeutics.

The report provides comprehensive information on the Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) targeted therapeutics development and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Potassium Voltage Gated Channel Subfamily KQT Member 2 Overview
  3. Therapeutics Development
  4. Pipeline Products for Potassium Voltage Gated Channel Subfamily KQT Member 2 - Overview
  5. Pipeline Products for Potassium Voltage Gated Channel Subfamily KQT Member 2 - Comparative Analysis
  6. Potassium Voltage Gated Channel Subfamily KQT Member 2 - Therapeutics under Development by Companies
  7. Potassium Voltage Gated Channel Subfamily KQT Member 2 - Therapeutics under Investigation by Universities/Institutes
  8. Potassium Voltage Gated Channel Subfamily KQT Member 2 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Potassium Voltage Gated Channel Subfamily KQT Member 2 - Products under Development by Companies
  13. Potassium Voltage Gated Channel Subfamily KQT Member 2 - Products under Investigation by Universities/Institutes
  14. Potassium Voltage Gated Channel Subfamily KQT Member 2 - Companies Involved in Therapeutics Development

- 1st Order Pharmaceuticals Inc

- Bristol-Myers Squibb Company

- Grunenthal GmbH

- Knopp Biosciences LLC

- Saniona AB

- SciFluor Life Sciences LLC

- Valeant Pharmaceuticals International Inc

For more information about this report visit http://www.researchandmarkets.com/research/xhsxfs/potassium_voltage